Phase I study of combination chemotherapy with nab-paclitaxel and Nedaplatin as first-line treatment in patients with advanced squamous cell lung cancer.
Phase of Trial: Phase I
Latest Information Update: 21 Jun 2017
Price : $35 *
At a glance
- Drugs Nedaplatin (Primary) ; Paclitaxel (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- 17 Jun 2017 Status changed from active, no longer recruiting to completed.
- 02 May 2017 Status changed from not yet recruiting to active, no longer recruiting, according to the results published in the Investigational New Drugs
- 02 May 2017 Results published in the Investigational New Drugs